Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 2/20 | 0.52 |
| ▸ | NOS1 | P29475 | 2/20 | 0.47 |
| ▸ | NOS2 | P35228 | 2/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL221820 | 0.78 | LMNA (0.45) | FFAR1 | |
| SCHEMBL4427549 | 0.76 | KCNH2 (0.55) | APPNOS1TSHRKCNH2 | |
| SCHEMBL224970 | 0.74 | LMNA (0.50) | — | |
| SCHEMBL223976 | 0.74 | RXRA (0.43) | KCNH2 | |
| SCHEMBL2741615 | 0.73 | TAAR1 (0.52) | APP | |
| Water SCHEMBL27907306 | 0.73 | RXRA (0.42) | KCNH2 | |
| SCHEMBL7455570 | 0.72 | APP (0.60) | APPNOS1NOS2BCHEACHE | |
| SCHEMBL9719817 | 0.72 | CYSLTR1 (0.66) | NOS1NOS2 | |
| SCHEMBL6962789 | 0.72 | APP (0.74) | APPNOS1NOS2BCHE | |
| SCHEMBL5206663 | 0.72 | DRD2 (0.48) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004230-A1 | IMIDAZOLE DERIVATIVES | GALLEY GUIDO (DE) | 2012-01-05 | — | — | US | claimed |
| US-20100204233-A1 | IMIDAZOLE DERIVATIVES | GALLEY GUIDO | 2010-08-12 | — | — | US | claimed |
| US-20080146523-A1 | IMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-06-19 | — | — | US | claimed |
| US-8399463-B2 | Imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20120004230-A1 | IMIDAZOLE DERIVATIVES | GALLEY GUIDO (DE) | 2012-01-05 | — | — | US | disclosed |
| US-20100204233-A1 | IMIDAZOLE DERIVATIVES | GALLEY GUIDO | 2010-08-12 | — | — | US | disclosed |
| EP-2094668-A2 | 4-IMIDAZOLINES AS TAAR'S LIGANDS | F. Hoffmann-Roche AG (CH) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008074679-A2 | 4-IMIDAZOLINES AS TAAR'S LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-26 | — | — | WO | disclosed |
| US-20080146523-A1 | IMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204233-A1 | IMIDAZOLE DERIVATIVES | TAAR1, TAAR5, TACR1 | APP 1629/4885NOS1 663/4885NOS2 586/4885 |
| US-20120004230-A1 | IMIDAZOLE DERIVATIVES | TAAR1, TAAR5, TACR1 | APP 1629/4885NOS1 663/4885NOS2 586/4885 |
| US-20080146523-A1 | IMIDAZOLE DERIVATIVES | TAAR1, TAAR5, TACR1 | APP 1629/4885NOS1 663/4885NOS2 586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.